Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for cardiovascular disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovasculardisease in primary care Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovasculardisease in primary care: 2018 update | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Guideline Canadian Cardiovascular Harmonized National Guidelines Endeavour (C (...) -CHANGE) guideline for the prevention and management of cardiovasculardisease in primary care: 2018 update Sheldon W. Tobe , James A. Stone , Todd Anderson , Simon Bacon , Alice Y.Y. Cheng , Stella S. Daskalopoulou , Justin A. Ezekowitz , Jean C. Gregoire , Gord Gubitz , Rahul Jain , Karim Keshavjee , Patty Lindsay , Mary L’Abbe , David C.W. Lau , Lawrence A. Leiter , Eileen O’Meara , Glen J. Pearson , Doreen M. Rabi , Diana Sherifali , Peter Selby , Jack V. Tu , Sean Wharton , Kimberly M. Walker
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovasculardisease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. BACKGROUND: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular (...) death, myocardial infarction, or stroke. METHODS: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovasculardisease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30-50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used
Tai Chi exercise is more effective than brisk walking in reducing cardiovasculardisease risk factors among adults with hypertension: A randomised controlled trial 30195124 2018 10 10 1873-491X 88 2018 Aug 24 International journal of nursing studies Int J Nurs Stud Tai Chi exercise is more effective than brisk walking in reducing cardiovasculardisease risk factors among adults with hypertension: A randomised controlled trial. 44-52 S0020-7489(18)30201-3 10.1016/j.ijnurstu.2018.08.009 Physical (...) inactivity is a major modifiable lifestyle risk factor associated with cardiovasculardisease. Tai Chi is a safe and popular form of physical activity among older adults, yet direct comparisons are lacking between Tai Chi and brisk walking in their ability to reduce cardiovasculardisease risk factors and improve psychosocial well-being. 246 adults (mean age = 64.4 ± 9.8 years, age range = 30-91 years, 45.5% men) with hypertension and at least two but not more than three modifiable cardiovasculardisease
Editorial: Extracellular Vesicle-Mediated Processes in CardiovascularDiseases 30283791 2018 12 19 2297-055X 5 2018 Frontiers in cardiovascular medicine Front Cardiovasc Med Editorial: Extracellular Vesicle-Mediated Processes in CardiovascularDiseases. 133 10.3389/fcvm.2018.00133 Koenen Rory R RR Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands. Aikawa Elena E Cardiovascular Division, Department of Medicine, Center
Association of dairy intake with cardiovasculardisease and mortality in 21 countries from five continents (PURE): a prospective cohort study. BACKGROUND: Dietary guidelines recommend minimising consumption of whole-fat dairy products, as they are a source of saturated fats and presumed to adversely affect blood lipids and increase cardiovasculardisease and mortality. Evidence for this contention is sparse and few data for the effects of dairy consumption on health are available from (...) low-income and middle-income countries. Therefore, we aimed to assess the associations between total dairy and specific types of dairy products with mortality and major cardiovasculardisease. METHODS: The Prospective Urban Rural Epidemiology (PURE) study is a large multinational cohort study of individuals aged 35-70 years enrolled from 21 countries in five continents. Dietary intakes of dairy products for 136 384 individuals were recorded using country-specific validated food frequency questionnaires
Environmental toxic metal contaminants and risk of cardiovasculardisease: systematic review and meta-analysis. OBJECTIVE: To conduct a systematic review and meta-analysis of epidemiological studies investigating the association of arsenic, lead, cadmium, mercury, and copper with cardiovasculardisease. DESIGN: Systematic review and meta-analysis. DATA SOURCES: PubMed, Embase, and Web of Science searched up to December 2017. REVIEW METHODS: Studies reporting risk estimates for total (...) cardiovasculardisease, coronary heart disease, and stroke for levels of arsenic, lead, cadmium, mercury, or copper were included. Two investigators independently extracted information on study characteristics and outcomes in accordance with PRISMA and MOOSE guidelines. Relative risks were standardised to a common scale and pooled across studies for each marker using random effects meta-analyses. RESULTS: The review identified 37 unique studies comprising 348 259 non-overlapping participants, with 13 033
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovasculardisease (ARRIVE): a randomised, double-blind, placebo-controlled trial. BACKGROUND: The use of aspirin in the primary prevention of cardiovascular events remains controversial. We aimed to assess the efficacy and safety of aspirin versus placebo in patients with a moderate estimated risk of a first cardiovascular event. METHODS: ARRIVE is a randomised, double-blind, placebo-controlled (...) , multicentre study done in seven countries. Eligible patients were aged 55 years (men) or 60 years (women) and older and had an average cardiovascular risk, deemed to be moderate on the basis of the number of specific risk factors. We excluded patients at high risk of gastrointestinal bleeding or other bleeding, or diabetes. Patients were randomly assigned (1:1) with a computer-generated randomisation code to receive enteric-coated aspirin tablets (100 mg) or placebo tablets, once daily. Patients
Extracellular Vesicles as Biomarkers in CardiovascularDisease; Chances and Risks 30186839 2018 11 14 2297-055X 5 2018 Frontiers in cardiovascular medicine Front Cardiovasc Med Extracellular Vesicles as Biomarkers in CardiovascularDisease; Chances and Risks. 113 10.3389/fcvm.2018.00113 The field of extracellular vesicles (EV) is rapidly expanding, also within cardiovasculardiseases. Besides their exciting roles in cell-to-cell communication, EV have the potential to serve as excellent (...) biomarkers, since their counts, content, and origin might provide useful information about the pathophysiology of cardiovascular disorders. Various studies have already indicated associations of EV counts and content with cardiovasculardiseases. However, EV research is complicated by several factors, most notably the small size of EV. In this review, the advantages and drawbacks of EV-related methods and applications as biomarkers are highlighted. Dickhout Annemiek A Department of Biochemistry
Urinary sodium excretion, blood pressure, cardiovasculardisease, and mortality: a community-level prospective epidemiological cohort study. BACKGROUND: WHO recommends that populations consume less than 2 g/day sodium as a preventive measure against cardiovasculardisease, but this target has not been achieved in any country. This recommendation is primarily based on individual-level data from short-term trials of blood pressure (BP) without data relating low sodium intake to reduced (...) cardiovascular events from randomised trials or observational studies. We investigated the associations between community-level mean sodium and potassium intake, cardiovasculardisease, and mortality. METHODS: The Prospective Urban Rural Epidemiology study is ongoing in 21 countries. Here we report an analysis done in 18 countries with data on clinical outcomes. Eligible participants were adults aged 35-70 years without cardiovasculardisease, sampled from the general population. We used morning fasting
Excess mortality and cardiovasculardisease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. BACKGROUND: People with type 1 diabetes are at elevated risk of mortality and cardiovasculardisease, yet current guidelines do not consider age of onset as an important risk stratifier. We aimed to examine how age at diagnosis of type 1 diabetes relates to excess mortality and cardiovascular risk. METHODS: We did a nationwide, register-based (...) cohort study of individuals with type 1 diabetes in the Swedish National Diabetes Register and matched controls from the general population. We included patients with at least one registration between Jan 1, 1998, and Dec 31, 2012. Using Cox regression, and with adjustment for diabetes duration, we estimated the excess risk of all-cause mortality, cardiovascular mortality, non-cardiovascular mortality, acute myocardial infarction, stroke, cardiovasculardisease (a composite of acute
Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovasculardisease in the ODYSSEY phase 3 trials 29802688 2018 07 02 1463-1326 2018 May 26 Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovasculardisease in the ODYSSEY phase 3 trials. 10.1111/dom.13384 Individuals with both diabetes mellitus (DM) and atherosclerotic cardiovasculardisease (...) , Sanofi, Chilly-Mazarin, France. IviData Stats, Levallois-Perret, France. Letierce Alexia A Biostatistics and Programming, Sanofi, Chilly-Mazarin, France. Leiter Lawrence A LA http://orcid.org/0000-0002-1040-6229 Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. eng Journal Article 2018 05 26 England Diabetes Obes Metab 100883645 1462-8902 cardiovasculardisease clinical trial dyslipidaemia lipid-lowering therapy 2018 03 29 2018 05 14 2018 05 23
Cardiovasculardisease Top results for cardiovasculardisease - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top (...) search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for cardiovasculardisease The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection
Remote ECG interpretation consultancy services for cardiovasculardisease Remote ECG interpretation consultancy services Remote ECG interpretation consultancy services for cardio for cardiovasculardisease vascular disease Medtech innovation briefing Published: 27 July 2018 nice.org.uk/guidance/mib152 pathways Summary Summary The technologies technologies described in this briefing are remote electrocardiogram (ECG) interpretation consultancy services. They are used for assisting in diagnosing (...) and decision-making for people with cardiovasculardisease. The inno innovativ vative aspects e aspects are that with remote ECG interpretation, a person does not need to travel to hospital for a consultation with a cardiologist, potentially providing quicker and more accurate diagnoses. The intended place in ther place in therap apy y would be to replace referrals to secondary care for interpreting ECGs from people with suspected cardiovasculardisease. The main points from the e main points from
Development and validation of a cardiovasculardisease risk-prediction model using population health surveys: the CardiovascularDisease Population Risk Tool (CVDPoRT) 30037888 2018 07 27 1488-2329 190 29 2018 Jul 23 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Development and validation of a cardiovasculardisease risk-prediction model using population health surveys: the CardiovascularDisease Population Risk Tool (CVDPoRT). E871-E882 10.1503 (...) /cmaj.170914 Routinely collected data from large population health surveys linked to chronic disease outcomes create an opportunity to develop more complex risk-prediction algorithms. We developed a predictive algorithm to estimate 5-year risk of incident cardiovasculardisease in the community setting. We derived the CardiovascularDisease Population Risk Tool (CVDPoRT) using prospectively collected data from Ontario respondents of the Canadian Community Health Surveys, representing 98
Performance of CardiovascularDisease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register 30002197 2018 08 15 1935-5548 2018 Jul 12 Diabetes care Diabetes Care Performance of CardiovascularDisease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register. dc180578 10.2337/dc18-0578 To evaluate the performance of five cardiovasculardisease (CVD (...) ) risk scores developed in diabetes populations and compare their performance to QRISK2. A cohort of people diagnosed with type 2 diabetes between 2004 and 2016 was identified from the Scottish national diabetes register. CVD events were identified using linked hospital and death records. Five-year risk of CVD was estimated using each of QRISK2, ADVANCE, Cardiovascular Healthy Study (CHS), New Zealand Diabetes Cohort Study (NZ DCS), Fremantle Diabetes Study, and Swedish National Diabetes Register
Prediction of cardiovasculardisease among hematopoietic cell transplantation survivors 30037802 2018 11 14 2473-9537 2 14 2018 Jul 24 Blood advances Blood Adv Prediction of cardiovasculardisease among hematopoietic cell transplantation survivors. 1756-1764 10.1182/bloodadvances.2018019117 Cardiovasculardisease (CVD) is a leading cause of late morbidity and mortality in hematopoietic cell transplantation (HCT) survivors. HCT-specific CVD risk prediction models are needed to facilitate early (...) screening and prevention. In the current study, patients who underwent HCT at City of Hope (COH) and survived 1-year free of clinically evident CVD (N = 1828) were observed for the development of heart failure (HF) or coronary artery disease (CAD) by 10-years from index date (1 year from HCT). CVD occurred in 135 individuals (92 HF, 43 CAD). Risk prediction models were developed for overall CVD (HF and/or CAD) using COH-derived integer risk scores. Risk scores based on selected variables (age
Blood pressure targets for the treatment of people with hypertension and cardiovasculardisease. BACKGROUND: This is the first update of the review published in 2017. Hypertension is a prominent preventable cause of premature morbidity and mortality. People with hypertension and established cardiovasculardisease are at particularly high risk, so reducing blood pressure to below standard targets may be beneficial. This strategy could reduce cardiovascular mortality and morbidity but could also (...) increase adverse events. The optimal blood pressure target in people with hypertension and established cardiovasculardisease remains unknown. OBJECTIVES: To determine if 'lower' blood pressure targets (≤ 135/85 mmHg) are associated with reduction in mortality and morbidity as compared with 'standard' blood pressure targets (≤ 140 to 160/90 to 100 mmHg) in the treatment of people with hypertension and a history of cardiovasculardisease (myocardial infarction, angina, stroke, peripheral vascular